The GLP-1 receptor agonist revolution comes to nephrology

Glucagon-like peptide 1 receptor agonists improve glucose control, promote weight loss and reduce the risk of major cardiovascular events in people with type 2 diabetes mellitus. The FLOW study now provides unequivocal evidence of kidney protective effects with semaglutide in adults with type 2 diab...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Nephrology 2024-10, Vol.20 (10), p.637-638
Main Authors: Thomas, Merlin C., Cooper, Mark E.
Format: Article
Language:English
Subjects:
692/163/2743/137/138
692/4022/1585/104/1586
Cardiovascular disease
Diabetes
GLP-1 receptor agonists
Glucagon
Glucose
Kidney diseases
Medicine
Medicine & Public Health
Mortality
Nephrology
News & Views
news-and-views
Obesity
Peptides
Weight control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucagon-like peptide 1 receptor agonists improve glucose control, promote weight loss and reduce the risk of major cardiovascular events in people with type 2 diabetes mellitus. The FLOW study now provides unequivocal evidence of kidney protective effects with semaglutide in adults with type 2 diabetes mellitus and chronic kidney disease.
ISSN:1759-5061
1759-507X
1759-507X
DOI:10.1038/s41581-024-00876-4